[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-remodeling\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-remodeling":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652467","cold-region-exposure-and-cardiac-remodeling-after-pci-100652467",false,"NCT07773870","Cold-Region Exposure and Cardiac Remodeling After PCI","Association of Cumulative Cold-Region Exposure With Left Ventricular Remodeling and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Multicenter Prospective Observational Cohort Study","COLD-PCI","Inclusion Criteria:\n\n* Age 18 to 75 years. Angiographically confirmed coronary artery disease treated with successful percutaneous coronary intervention, defined as residual stenosis \\\u003C30% with final TIMI grade 3 flow.\n\nClinically stable after PCI. Expected survival of at least 12 months. Able and willing to undergo baseline cardiovascular magnetic resonance imaging and baseline and 6-month transthoracic echocardiography.\n\nAble to provide residential, occupational, training\u002Fdeployment, and other relevant exposure histories for the 3 years preceding PCI.\n\nWritten informed consent provided.\n\nExclusion Criteria:\n\n* Severe valvular heart disease, cardiomyopathy, congenital heart disease, or other major structural heart disease.\n\nPrevious coronary artery bypass grafting or heart transplantation. End-stage heart failure or New York Heart Association class IV heart failure. Severe renal dysfunction, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m².\n\nKnown contraindication to cardiovascular magnetic resonance imaging or gadolinium-based contrast agents.\n\nInability to complete transthoracic echocardiographic assessment. Inability to reliably recall or verify major residential or occupational exposure history during the 3 years preceding PCI.\n\nMore than five major changes in primary residence during the 3 years preceding PCI that preclude reliable estimation of cumulative cold-region exposure.","ALL","18 Years","80 Years",{"count":21,"type":22},400,"ESTIMATED","12 Months","OBSERVATIONAL","This multicenter prospective observational cohort study aims to investigate the association between cumulative cold-region exposure and adverse left ventricular remodeling and cardiovascular outcomes in patients with coronary artery disease undergoing successful percutaneous coronary intervention (PCI).\n\nIndividual-level chronic cold exposure will be quantified primarily by cumulative months of residence, work, or other relevant exposure in cold regions during the 3 years preceding PCI. Additional exposure measures will include regional cold-wave days derived from meteorological records and winter outdoor occupational exposure.\n\nParticipants will undergo baseline cardiovascular magnetic resonance (CMR), echocardiography, electrocardiography, and clinical and laboratory assessment after PCI. Echocardiography will be repeated at 6 months to assess left ventricular remodeling. Cardiovascular events will be prospectively collected during follow-up.\n\nThe study will evaluate whether cumulative cold-region exposure is associated with distinct CMR phenotypes, adverse left ventricular remodeling, and major adverse cardiovascular events (MACE), and whether cold-exposure measures provide incremental prognostic information beyond conventional clinical, imaging, and electrocardiographic risk markers.",[27,28,29,30],"Coronary Artery Disease","Percutaneous Coronary Intervention (PCI)","Left Ventricular Remodeling","Cold Exposure",[29,32,30,33],"Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction","RECRUITING","2026-08-16",{"date":37,"type":38},"2026-08-19","ACTUAL",{"date":40,"type":38},"2026-06-30",{"date":42,"type":22},"2028-12-30",{"name":44,"class":45},"Chinese PLA General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100584152","prediction-of-lvar-and-mace-in-stemi-though-plasma-multiomics-analysis-100584152","NCT06885619","Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis","Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute ST-segment Elevation Myocardial Infarction Though Plasma Multiomics Analysis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years.\n2. Definite diagnosis of STEMI according to ESC\u002FACC guidelines:\n\n   * Chest pain lasting \\>30 minutes, and\n   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.\n3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).\n4. First STEMI (no prior history of myocardial infarction).\n5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.\n6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.\n2. Severe comorbidities:\n\n   * Prior HF (NYHA ≥II);\n   * Severe CKD (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis);\n   * Severe liver disease (Child-Pugh B\u002FC);\n   * Active malignancy (life expectancy \\\u003C1 year);\n   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).\n3. Fibrinolysis-followed-by-PCI.\n4. Primary PCI complications:\n\n   * No-reflow\u002Fslow-flow (final TIMI \\\u003C2);\n   * Cardiogenic shock or mechanical complication within 7 days;\n   * In-hospital repeat revascularization.\n5. Inability to complete 6-month follow-up.\n6. Factors affecting blood sampling\u002Fexosome\u002Fimmune\u002Fproteome assays:\n\n   * Blood transfusion within 1 month;\n   * Known hemolytic disorder;\n   * Inadequate venous access.\n7. Pregnancy or lactation.",{"count":55,"type":22},1000,"To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.",[29,58,59,60,61],"Plasma Multi-Omics","Acute ST-segment Elevation Myocardial Infarction","Immunomics","Major Adverse Cardiovascular Events","2026-05-07",{"date":64,"type":38},"2026-05-12",{"date":66,"type":38},"2025-05-01",{"date":68,"type":22},"2027-12-31",{"name":70,"class":45},"Beijing Anzhen Hospital"]